Polypharmacy More Likely for Cancer Survivors

Share this content:
Polypharmacy More Likely for Cancer Survivors
Polypharmacy More Likely for Cancer Survivors

WEDNESDAY, April 18, 2018 (HealthDay News) -- Cancer survivors are more likely to be prescribed five or more unique medications, including drugs with abuse potential, according to a study published online April 12 in Cancer.

Caitlin C. Murphy, Ph.D., M.P.H., from the University of Texas Southwestern Medical Center in Dallas, and colleagues used data from the Medical Expenditure Panel Survey for 5,216 cancer survivors and 19,588 non-cancer controls matched by age, sex, and survey year to examine patterns of prescription medication use and polypharmacy.

The researchers found that, compared with non-cancer controls, a higher percentage of cancer survivors were prescribed five or more unique medications (64 versus 51.5 percent), including drugs with abuse potential. Compared with controls, a higher percentage of newly (one year or less since diagnosis) and previously (more than one year since diagnosis) diagnosed survivors were prescribed medications, with large differences with respect to central nervous system agents (65.8 versus 57.4 versus 46 percent). Benzodiazepines and/or opioids were prescribed to nearly 10 percent of survivors and about 5 percent of controls. Survivors' prescription expenditures were more than double those of controls (median, $1,633 versus $784). Across age and comorbidity categories, the findings persisted.

"Cancer survivors were prescribed a higher number of unique medications, including drugs with abuse potential, thereby increasing their risk of adverse drug events, financial toxicity, poor adherence, and drug-drug interactions," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »